These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19216215)

  • 1. Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.
    Sepulveda Sanchez JM; Martinez Montero JC; Diez-Lobato R; Hernandez-Lain A; Cabello A; Ramos A; Gonzalez Leon P; Ricoy Campo JR
    Clin Neuropathol; 2009; 28(1):11-20. PubMed ID: 19216215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The presence of necrosis and/or microvascular proliferation does not influence survival of patients with anaplastic oligodendroglial tumours: review of 98 patients.
    Smith SF; Simpson JM; Brewer JA; Sekhon LH; Biggs MT; Cook RJ; Little NS
    J Neurooncol; 2006 Oct; 80(1):75-82. PubMed ID: 16794749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
    Panageas KS; Reiner AS; Iwamoto FM; Cloughesy TF; Aldape KD; Rivera AL; Eichler AF; Louis DN; Paleologos NA; Fisher BJ; Ashby LS; Cairncross JG; Urgoiti GB; Wen PY; Ligon KL; Schiff D; Robins HI; Rocque BG; Chamberlain MC; Mason WP; Weaver SA; Green RM; Kamar FG; Abrey LE; DeAngelis LM; Jhanwar SC; Rosenblum MK; Lassman AB
    Neuro Oncol; 2014 Nov; 16(11):1541-6. PubMed ID: 24997140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
    Miller CR; Dunham CP; Scheithauer BW; Perry A
    J Clin Oncol; 2006 Dec; 24(34):5419-26. PubMed ID: 17135643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicohistological study of oligodendroglioma and oligoastrocytoma.
    Tamura M; Zama A; Kurihara H; Kano T; Imai H; Ishiuchi S; Iwai T; Naito I
    Brain Tumor Pathol; 1997; 14(1):35-9. PubMed ID: 9384800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas.
    Tortosa A; Viñolas N; Villà S; Verger E; Gil JM; Brell M; Caral L; Pujol T; Acebes JJ; Ribalta T; Ferrer I; Graus F
    Cancer; 2003 Feb; 97(4):1063-71. PubMed ID: 12569607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies].
    Daumas-Duport C; Koziak M; Miquel C; Nataf F; Jouvet A; Varlet P
    Neurochirurgie; 2005 Sep; 51(3-4 Pt 2):247-53. PubMed ID: 16292168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading.
    Giannini C; Scheithauer BW; Weaver AL; Burger PC; Kros JM; Mork S; Graeber MB; Bauserman S; Buckner JC; Burton J; Riepe R; Tazelaar HD; Nascimento AG; Crotty T; Keeney GL; Pernicone P; Altermatt H
    J Neuropathol Exp Neurol; 2001 Mar; 60(3):248-62. PubMed ID: 11245209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Outcomes in 1p19q Co-deleted/Partially Deleted Gliomas.
    McNamara MG; Jiang H; Lim-Fat MJ; Sahebjam S; Kiehl TR; Karamchandani J; Coire C; Chung C; Millar BA; Laperriere N; Mason WP
    Can J Neurol Sci; 2017 May; 44(3):288-294. PubMed ID: 28488951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of malignant features in oligodendroglial tumors.
    Saito A; Nakazato Y
    Clin Neuropathol; 1999; 18(2):61-73. PubMed ID: 10192700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
    Kim JW; Park CK; Park SH; Kim YH; Han JH; Kim CY; Sohn CH; Chang KH; Jung HW
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):224-7. PubMed ID: 20587495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.
    Zetterling M; Berhane L; Alafuzoff I; Jakola AS; Smits A
    PLoS One; 2017; 12(11):e0188419. PubMed ID: 29186201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.
    Hamlat A; Saikali S; Chaperon J; Carsin-Nicol B; Calve ML; Lesimple T; Ben-hassel M; Guegan Y
    J Neurooncol; 2006 Sep; 79(2):159-68. PubMed ID: 16821091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of perfusion MR imaging in patients with oligodendroglioma: A survival study.
    Jiang Z; Le Bas JF; Grand S; Salon C; Pasteris C; Hoffmann D; Bing F; Berger F; Chabardes S; Liu C; Krainik A
    J Neuroradiol; 2011 Mar; 38(1):53-61. PubMed ID: 20554324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas.
    Kanno H; Nishihara H; Narita T; Yamaguchi S; Kobayashi H; Tanino M; Kimura T; Terasaka S; Tanaka S
    PLoS One; 2012; 7(7):e41669. PubMed ID: 22911839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?
    Bisdas S; Kirkpatrick M; Giglio P; Welsh C; Spampinato MV; Rumboldt Z
    AJNR Am J Neuroradiol; 2009 Apr; 30(4):681-8. PubMed ID: 19179427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of oligodendrogliomas.
    Lebrun C; Fontaine D; Ramaioli A; Vandenbos F; Chanalet S; Lonjon M; Michiels JF; Bourg V; Paquis P; Chatel M; Frenay M;
    Neurology; 2004 May; 62(10):1783-7. PubMed ID: 15159478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.